Violation Tracker Industry Summary Page
Industry:
pharmaceuticals
Penalty Total since 2000:
$32,446,957,557
Number of Records:
449
Note:
The total includes only those entries matched to a parent company. The industry designation is the primary one for the parent's operations overall. The penalty dollar total above is adjusted to account for the fact that the list of entries below may include both agency records and settlement announcements for the same case; or else a penalty covering multiple locations may be listed in the individual records for each of the facilities. Duplicate penalty amounts are marked with an asterisk in the individual records list below.
| Top 10 Parent Companies | Total Penalty $ | Number of Records |
|---|---|---|
| Pfizer | $4,419,846,055 | 46 |
| GlaxoSmithKline | $3,967,997,982 | 13 |
| Johnson & Johnson | $3,370,247,328 | 27 |
| Merck | $2,943,257,640 | 38 |
| Abbott Laboratories | $2,338,807,423 | 25 |
| Teva Pharmaceutical Industries | $2,182,020,831 | 25 |
| Eli Lilly | $1,482,270,176 | 13 |
| Novartis | $1,221,184,386 | 22 |
| Allergan | $1,098,851,374 | 13 |
| Bristol-Myers Squibb | $985,938,245 | 17 |
Individual Penalty Records:
Download results as 
or XML
or XML
| Company | Parent | Primary Offense Type | Year | Agency |
Penalty Amount |
|---|---|---|---|---|---|
| GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
| Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
| Abbott Laboratories Inc. | Abbott Laboratories | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Cephalon, Inc. | Teva Pharmaceutical Industries | consumer protection violation | 2015 | FTC | $1,200,000,000 |
| Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| TAP Pharmaceutical Products Inc. | Takeda Pharmaceutical | False Claims Act | 2001 | DOJ_CIVIL | $875,000,000 |
| Pfizer Inc. | Pfizer | False Claims Act | 2016 | DOJ_CIVIL | $784,600,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | FDA | $750,000,000 |
| Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
| Merck & Company | Merck | False Claims Act | 2008 | DOJ_CIVIL | $650,000,000 |
| Allergan Inc. | Allergan | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Abbott Laboratories and CG Nutritionals | Abbott Laboratories | False Claims Act | 2003 | DOJ_CIVIL | $600,000,000 |
| AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
| Ranbaxy USA Inc. | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | FDA | $500,000,000 |
| Schering-Plough Corporation | Merck | drug or medical equipment safety violation | 2002 | DOJ_CIVIL | $500,000,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| Mylan Inc. | Mylan | False Claims Act | 2017 | DOJ_CIVIL | $465,000,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act | 2007 | USAO | $461,900,000 |
| Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
| Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
| Cephalon Inc | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Novartis Pharmaceuticals | Novartis | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Actelion Pharmaceuticals US, Inc. | Johnson & Johnson | False Claims Act | 2018 | DOJ_CIVIL | $360,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | False Claims Act | 2003 | DOJ_CIVIL | $354,900,000 |
| Shire Pharmaceuticals LLC | Shire | False Claims Act | 2017 | DOJ_CIVIL | $350,000,000 |
| Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | DOJ_CIVIL | $345,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | fraud | 2005 | USAO | $300,000,000 |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | DOJ_CRIMINAL | $283,177,348 |
| Dey Inc. | Mylan | False Claims Act | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | False Claims Act | 2010 | DOJ_CIVIL | $280,000,000 |
| Celgene Corp. | Celgene | False Claims Act | 2017 | USAO | $280,000,000 |
| Teva Pharmaceutical Industries Limited | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | SEC | $236,000,000 |
| United Therapeutics Corporation | United Therapeutics | False Claims Act | 2017 | DOJ_CIVIL | $210,000,000 |
| Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | False Claims Act | 2007 | DOJ_CIVIL | $190,000,000 |
| Novartis Corporation | Novartis | employment discrimination | 2010 | private lawsuit-federal | $175,000,000 |
| Forest Pharmaceuticals Inc. | Allergan | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | False Claims Act | 2005 | DOJ_CIVIL | $150,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Forest Pharmaceuticals Inc. | Allergan | False Claims Act | 2010 | USAO | $149,000,000 |
| Abbott Laboratories Inc. | Abbott Laboratories | False Claims Act | 2010 | DOJ_CIVIL | $126,500,000 |
| Warner Chilcott PLC | Allergan | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| King Pharmaceuticals | Pfizer | False Claims Act | 2005 | DOJ_CIVIL | $124,000,000 |
| Mylan Pharmaceuticals and UDL Laboratories | Mylan | False Claims Act | 2009 | DOJ_CIVIL | $118,000,000 |
| Sanofi-Aventis U.S. Inc. | Sanofi | False Claims Act | 2012 | DOJ_CIVIL | $109,000,000 |
| Mylan Laboratories, Inc. | Mylan | consumer protection violation | 2000 | FTC | $100,000,000 |
| Mallinckrodt ARD Inc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | FTC | $100,000,000 |
| Novartis | Novartis | wage and hour violation | 2012 | private lawsuit-federal | $99,000,000 |
| Aventis Pharmaceutical Inc. | Sanofi | False Claims Act | 2009 | DOJ_CIVIL | $95,500,000 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Boehringer Ingelheim | off-label or unapproved promotion of medical products | 2012 | FDA | $95,000,000 |
| Scios Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2011 | FDA | $85,000,000 |
| Depuy Orthopaedics Inc. | Johnson & Johnson | False Claims Act | 2007 | USAO | $84,700,000 |
| Ortho-McNeil Pharmaceutical LLC | Johnson & Johnson | off-label or unapproved promotion of medical products | 2010 | FDA | $81,000,000 |
| Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $72,500,000 |
| Genentech Inc. | Roche | False Claims Act | 2016 | DOJ_CIVIL | $67,000,000 |
| OSI Pharmaceuticals LLC | Astellas Pharma | False Claims Act | 2016 | DOJ_CIVIL | $67,000,000 |
| Novo Nordisk Inc. | Novo A/S | False Claims Act | 2017 | DOJ_CIVIL | $58,650,000 |
| Shire Pharmaceuticals LLC | Shire | off-label or unapproved promotion of medical products | 2014 | FDA | $56,500,000 |
| Pfizer Inc. | Pfizer | drug or medical equipment safety violation | 2012 | FDA | $55,000,000 |
| Salix Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2016 | USAO | $54,000,000 |
| Pfizer Corporation | Pfizer | False Claims Act | 2002 | DOJ_CIVIL | $49,000,000 |
| Johnson & Johnson | Johnson & Johnson | Foreign Corrupt Practices Act | 2011 | SEC | $48,600,000 |
| SmithKline Beecham | GlaxoSmithKline | False Claims Act | 2003 | DOJ_CIVIL | $47,000,000 |
| AstraZeneca LP | AstraZeneca | False Claims Act | 2015 | DOJ_CIVIL | $46,500,000 |
| Par Pharmaceutical Companies Inc. | Endo International | off-label or unapproved promotion of medical products | 2013 | FDA | $45,000,000 |
| Serono Laboratories Inc. | Merck KGaA (EMD) | False Claims Act | 2011 | DOJ_CIVIL | $44,300,000 |
| Alpharma Inc. | Pfizer | False Claims Act | 2010 | DOJ_CIVIL | $42,500,000 |
| Kos Pharmaceuticals | AbbVie | kickbacks and bribery | 2010 | FDA | $41,500,000 |
| Daiichi Sankyo Inc. | Daiichi Sankyo | False Claims Act | 2015 | DOJ_CIVIL | $39,000,000 |
| Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals | Endo International | drug or medical equipment safety violation | 2015 | USAO | $39,000,000 |
| Forest Laboratories and Forest Pharmaceuticals | Allergan | False Claims Act | 2016 | DOJ_CIVIL | $38,000,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2005 | FDA | $36,000,000 |
| Mallinckrodt LLC | Mallinckrodt | Controlled Substances Act violation | 2017 | DEA | $35,000,000 |
| Aegerion Pharmaceuticals Inc. | Novelion Therapeutics | drug or medical equipment safety violation | 2017 | DOJ_CIVIL | $35,000,000 |
| UCB Inc. | UCB | off-label or unapproved promotion of medical products | 2011 | FDA | $34,000,000 |
| Alere Inc. | Abbott Laboratories | False Claims Act | 2018 | DOJ_CIVIL | $33,200,000 |
| Genzyme Corporation | Sanofi | drug or medical equipment safety violation | 2015 | FDA | $32,587,439 |
| Eli Lilly and Company | Eli Lilly | Foreign Corrupt Practices Act | 2012 | SEC | $29,398,734 |
| Ethex Corporation | KV Pharmaceutical | drug or medical equipment safety violation | 2010 | FDA | $27,600,000 |
| Teva Pharmaceuticals USA Inc. and IVAX LLC | Teva Pharmaceutical Industries | False Claims Act | 2014 | DOJ_CIVIL | $27,600,000 |
| Schering-Plough | Merck | False Claims Act | 2004 | DOJ_CIVIL | $27,000,000 |
| Pfizer Inc. | Pfizer | Foreign Corrupt Practices Act | 2012 | SEC | $26,339,944 |
| Sanofi | Sanofi | Foreign Corrupt Practices Act | 2018 | SEC | $25,200,000 |
| McNeil-PPC Inc. | Johnson & Johnson | drug or medical equipment safety violation | 2015 | FDA | $25,000,000 |
| Novo Nordisk Inc. | Novo A/S | off-label or unapproved promotion of medical products | 2011 | FDA | $25,000,000 |
| Novartis AG | Novartis | Foreign Corrupt Practices Act | 2016 | SEC | $25,000,000 |
| Abbott Laboratories | Abbott Laboratories | off-label or unapproved promotion of medical products | 2018 | USAO | $25,000,000 |
| Amgen Inc. | Amgen | False Claims Act | 2013 | DOJ_CIVIL | $24,900,000 |
| Biovail Pharmaceuticals Inc. | Bausch Health | kickbacks and bribery | 2009 | USAO | $24,647,876 |
| Pfizer, Inc. | Pfizer | False Claims Act | 2018 | DOJ_CIVIL | $23,850,000 |
| Roussel Uclaf S.A. | Sanofi | drug or medical equipment safety violation | 2001 | USAO | $23,193,600 |
| Genzyme Corp. | Sanofi | False Claims Act | 2013 | DOJ_CIVIL | $22,280,000 |
| Johnson & Johnson | Johnson & Johnson | Foreign Corrupt Practices Act | 2011 | DOJ_CRIMINAL | $21,400,000 |
| GlaxoSmithKline plc | GlaxoSmithKline | kickbacks and bribery | 2016 | SEC | $20,000,000 |
Download results as or XML
or XML
